Carla Coffin

cscoffin@ucalgary.ca


In-person interactions impact on HCV, HIV, and Syphilis Rates in At Risk Populations

Pam Ford

Targeting the hepatitis B virus covalently closed circular DNA genome using a G-quadruplex specific single domain antibody

Simmone D'Souza

HDV is uncommon in Toronto but can have an aggressive clinical course: interim analysis

David Wong

Biologiste Médical

Ronald Simeon

Impact of COVID-19 pandemic–related measures on testing for hepatitis B in British Columbia, Canada: an interrupted time series analysis

Richard Morrow

Clinical Science Advances in Hepatitis B (HDV, HCV, HIV Co-infections): A Comprehensive Review

Moses Donkor

Epidemiology and Public Health Implications of Hepatitis B, HDV, HCV, and HIV Co-infections

Desmond Osei

EPIDEMIOLOGY, TREATMENT PATTERN, AND SURVIVAL IN CANADIAN PATIENTS WITH CHRONIC HEPATITIS B RELATED HEPATOCELLULAR CARCINOMA

Yashasavi Sachar

HCC RISK STRATIFICATION USING RANDOM SURVIVAL FORREST MACHINE LEARNING MODEL OUTPERFORMS TRADITIONAL ANALOG SCORING

Yashasavi Sachar

Hepatitis B core antibody is associated with liver fibrosis in people with HIV independently of MASLD

Dong Hyun (Danny) Kim

Initial HBV-Hepatocyte Genomic Integrations, Their Formation and Potential Role in Oncogenesis

Thomas Michalak

Investigating HDV screening rates and associated demographic characteristics among first-time HBV positive patients in Alberta from 2018-2022

Alexa Thompson

Compassionate use of REP 2139-Mg in HBV / HDV / HIV co-infection: a first Canadian experience

Sébastien Poulin

Functional cure of chronic HBV infection

David Wong

Using discrete field documentation in Epic EMR for clinical research of hepatitis B

David Wong

A DNA knot not like any other - exploring the specificity of HBV’s promoter G4-quadruplex

Archee Panwar

Intravital Imaging of the Liver Microenvironment in The Woodchuck Model of Hepatitis B Virus Infection

Layla Al-Yasiri

Chronic HBV infection in Toronto, Canada: Tale of two clinics

David Wong

Demographic Characteristics of Hepatitis B-Infected Sub-Saharan African Immigrants in Canada.

Nana Frimpong

Determining a Hepatitis Delta virus (HDV) peptidomimetic therapeutic to target Hepatitis B virus (HBV)

Justine Beghin

Anchoring Hepatitis B: Investigation of HBV promoter binding with zinc finger Specificity protein 1 and G4-quadruplex binding drugs

Samantha Polege

Epidemiology and Natural History of Chronic Hepatitis B in the Canadian Province of Alberta from 2012 to 2021: A Population-based Study

Golasa Samadi Kochaksaraei

Epidemiology, Linkage to Care and Natural History of Women of Childbearing Age with Chronic Hepatitis B: A Population-based Study

Golasa Samadi Kochaksaraei

Defining a Hepatitis D Virus Antibody Testing Algorithm for Accurate Screening

Carla Osiowy

IL-2 Produced by HBV-specific T cells as a Biomarker of Viral Control and Predictor of Response to PD-1 Therapy Across Clinical Phases of Chronic Hepa

Loghman Salimzadeh

Next Generation Sequence (NGS) Analysis for Hepatitis B Virus (HBV) Outbreak Transmission Analysis in Manitoba

Carla Osiowy

Prevalence and Clinical Characteristics of Hepatitis Delta Virus (HDV) Infected Individuals in British Columbia

Valeriya Zaborska

PSMA-Targeted Radionuclide Therapy of Hepatocellular Carcinoma in a Woodchuck Model

Hoda Poorbagher

G4Q-binding ligands: a starting point for potential cure therapies for chronic hepatitis B infections

Jessica Skoreyko

Cracking the HBV Code: Unravelling the specificity of SP1 with G-Quadruplex for next- generation cccDNA inhibitors

Kuldeep Kaur

Effect of HBV treatment on all-cause and liver-related death among individuals with HBV and cirrhosis in British Columbia: a population-based cohort

Jean Makuza

Hepatitis B Virus Genotype (GT) Does Not Influence Virological and Enzymatic Measures Over Time

Curtis Cooper

Prevalence of Hepatitis B Among Adults Receiving Immunosuppressive Therapy At a Tertiary Care Center in Saudi Arabia

Abdulrhman Alamr

Hepatocellular carcinoma (HCC) in patients followed in two clinics in Toronto

David Wong

Experience of a Chinese Hepatitis B Peer Support Group (PSG): Successes and Challenges

Colina Yim

Small molecules approach in HBV treatment:preventing transcription in the pre-core promoter by blocking a G-quadruplex with mithramycin and daunorubin

Kira Sviderskaia

Kinetics of Quantitative HBsAg Decline in Chronic Hepatitis B Patients Receiving Nucleos(t)ide Antiviral Therapy

Frank Hyun

Opening the X-files: Exploring HBx protein’s role in transcriptional enhancement

Emma Kasinyabo

Establishment of HBx responsive quantitative cell culture reporter system for monitoring HBV infection

Muhammad Atif Zahoor

Unravelling an important DNA knot – analysis of HBV’s promoter G4-quadruplex

Mohaddeseh Pakzamir

Production of recombinant woodchuck surface antigen and antibodies for use in ELISAs, ELISpots, and western blots

Michelle Tang

Anchoring Hepatitis B: Investigation of HBV promoter binding with zinc finger Specificity protein 1 and G4-quadruplex binding drugs

Samantha Polege

Guanine quadruplexes and host transcription factor interactions: Targeting viral cccDNA to treat chronic HBV.

Nikolas Shapka

Guanine quadruplexes and host transcription factor interactions: Targeting viral cccDNA to treat chronic HBV.

Nikolas Shapka

David Wong

Under Review

Profile Summary

Submission ID PRO052BZ5TC
Name David Wong
Call Progress toward Hepatitis B Elimination Meeting in Canada - Abstract Submission
Email Address dave.wong@uhn.ca
Title Hepatologist
Organization University Health Network
State/Province Ontario
City Toronto

Session

Title Using discrete field documentation in Epic EMR for clinical research of hepatitis B
Description

Title: Using discrete field documentation in Epic EMR for clinical research of hepatitis B

Background: Many centres are using electronic medical records (EMR) for clinical documentation. Our centre adopted Epic EMR in June 2022.

Purpose: Explore the feasibility of clinical documentation using discrete field documentation in Epic EMR to facilitate practice audit and clinical research.

Method: Discrete field documentation was used preferentially over free text documentation where possible: Surgical History: Liver biopsy, Endoscopy, HCC treatment; Medications; Social History: Race, Marital Status, Substance Use (Tobacco, Alcohol), Family History. Medical History leveraged redundancy in ICD-10 to categorize Hepatitis B status as Acute (B16.9), Undifferentiated chronic (B18.9), HBV without HDV (B18.1), HBV+HDV (B17.0), HBV without HDV, Immune Tolerant (B18.10). R76.8 was used as a marker of HBeAg positive status. Severity states such as cirrhosis, HCC, varices also documented in this manner. Data summarized using the SlicerDicer module of Epic.

Result(s): From June 6, 2022 to Jun 30, 2023, N=2,614 individual patients have been assessed. N=1,148 had HBV infection (2 acute). An additional 87 had functional cure of chronic HBV infection.

Conclusion(s): Discrete field clinical documentation can be used in a busy clinic to facilitate live clinical audits and facilitate research individually and potentially wider collaboration in the many sites that also use Epic EMR.

Track Hepatitis B (including HDV, HCV, HIV Co-infections) - Clinical Science
Formats
Audiences

Submit Review



Is this abstract accepted for a poster presentation? *
Is this abstract accepted for a trainee travel grant?